GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Other Current Assets

DiaMedica Therapeutics (DiaMedica Therapeutics) Other Current Assets : $0.41 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Other Current Assets?

DiaMedica Therapeutics's other current assets for the quarter that ended in Dec. 2023 was $0.41 Mil.

DiaMedica Therapeutics's quarterly other current assets increased from Jun. 2023 ($0.67 Mil) to Sep. 2023 ($1.11 Mil) but then declined from Sep. 2023 ($1.11 Mil) to Dec. 2023 ($0.41Mil).

DiaMedica Therapeutics's annual other current assets increased from Dec. 2021 ($0.20 Mil) to Dec. 2022 ($0.25 Mil) increased from Dec. 2022 ($0.25 Mil) to Dec. 2023 ($0.41 Mil).


DiaMedica Therapeutics Other Current Assets Historical Data

The historical data trend for DiaMedica Therapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Other Current Assets Chart

DiaMedica Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.07 0.20 0.25 0.41

DiaMedica Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.96 0.67 1.11 0.41

DiaMedica Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


DiaMedica Therapeutics Other Current Assets Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Executives
Jan Stahlberg 10 percent owner C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen officer: CFO and Secretary 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill 10 percent owner SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls director, officer: President and CEO 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto 10 percent owner 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke officer: Chief Business Officer 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt 10 percent owner C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von 10 percent owner TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise 10 percent owner C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves officer: SVP Clinical Development Oper. 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305